GICS Sector : Healthcare
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company.It engages in developing various therapeutic candidates that focuses on various mental health disorders.The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Enhanced Fortifies Executive Leadership Team & Board of Directors
Nov -20
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3
Nov -12
Oklo highlights operational milestones, progress towards Aurora commercialization in Q3
Nov -11
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript
Nov -11
AtaiBeckley reports positive data supporting repeated dosing of BPL-003 in treatment-resistant depression patients
Nov -10
atai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckley
Nov -05
atai Life Sciences closes $149.5M public offering, extending cash runway into 2029
Oct -21
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Oct -20
Growing demand for mental health treatments, increasing awareness of psychedelic compounds' potential, and advancements in digital therapeutics drive growth in Atai Life Sciences' novel therapeutics for mental health disorders.
A medication primarily used as an anesthetic agent for surgery and other painful procedures
A psychoactive drug known for its empathogenic and stimulant effects
A naturally occurring psychedelic compound found in certain species of mushrooms
A powerful psychedelic compound found in various plants and animals
A naturally occurring psychoactive compound found in the roots of the Tabernanthe iboga plant
A plant-based psychedelic brew traditionally used in shamanic rituals
Atai Life Sciences N.V. operates in a highly competitive industry, and there are several substitutes available for its products. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.
Atai Life Sciences N.V. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to its customers' operations, making it difficult for customers to negotiate prices.
Atai Life Sciences N.V. relies on a few key suppliers for certain raw materials, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk to some extent.
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. Atai Life Sciences N.V. needs to continuously innovate and invest in research and development to stay ahead of new entrants.
The biotechnology industry is highly competitive, and Atai Life Sciences N.V. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to maintain its market share.
| Value | |
|---|---|
| Debt Weight | 5.99% |
| Debt Cost | 8.56% |
| Equity Weight | 94.01% |
| Equity Cost | 8.56% |
| WACC | 8.56% |
| Leverage | 6.37% |
Value: 5.4
Growth: 8.1
Quality: 8.2
Yield: 0.0
Momentum: 5.5
Volatility: 5.3
1-Year Total Return ->
Value: 6.8
Growth: 2.4
Quality: 9.9
Yield: 5.0
Momentum: 2.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.0
Growth: 2.9
Quality: 5.0
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.2
Growth: 6.2
Quality: 3.9
Yield: 0.0
Momentum: 5.0
Volatility: 1.3
1-Year Total Return ->
Value: 1.1
Growth: 4.4
Quality: 7.8
Yield: 1.2
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 1.5
Growth: 2.6
Quality: 9.9
Yield: 0.0
Momentum: 5.0
Volatility: 0.3
1-Year Total Return ->